Visual Atlas · Critical thinking

Common myths debunked

Four myths that follow people into microdosing — and where each one is wrong, partly right, or genuinely unresolved. Across all four, the pattern is the same: people overestimate how much they need to do.

90-second quick read · deeper research available

Need the deeper research library?

This is the 90-second cliff-note read on imicrodosing.net. For cited research context, terminology, and broader education, use the full .org research library.

See the full myths-and-evidence review →Browse related 90-second reads →

4 mythsExamined

2021Szigeti self-blinded study

Sub-perceptualThe whole point

In brief

Four myths recur. That more is better — a microdose is sub-perceptual by definition, and pushing the dose up defeats the purpose. That you should feel a buzz — feeling the dose means it is no longer a microdose. That natural means safe — a natural compound still interacts with medication and varies in potency. And that microdosing is purely placebo.

The placebo question is the honest one. Szigeti et al. 2021, a large self-blinded study, found much of the reported benefit was matched by placebo, while other observational data shows directional effects. The reasonable position is that expectation plays a real role and a microdose-specific signal above it is unsettled. Across all four myths, people overestimate how much they need to do.

Visual walkthrough

Cover: common microdosing myths debunked — four claims and what the evidence actually shows.

Myth one, the claim: more is better — a bigger dose means a bigger benefit.

Slide explaining that “microdose” is an informal effect category rather than a universally standardized amount.

Myth two, the claim: you should feel a buzz or lift when it is working.

Slide discussing why noticeable effects do not establish effectiveness or an appropriate amount.

Myth three, the claim: it is natural, so it is safe.

Myth three, reality: natural compounds still interact with medication and vary widely in potency.

Myth four, the claim: microdosing is entirely placebo.

Slide summarizing mixed placebo-controlled and observational findings; the microdosing question remains unsettled.

Closing slide encouraging critical evaluation of common microdosing claims.

1 / 10

Swipe or tap the arrows to move through 10 slides

Four myths and what is actually true

More is not better

A microdose is sub-perceptual by definition — roughly a tenth of a recreational dose. Increasing it does not scale the benefit; it produces a noticeable, function-impairing low dose.

Feeling it means it is too high

If you feel a buzz, lift, or visual change, the dose has crossed out of microdose range. The intended effect is cumulative and retrospective, not acute.

Natural is not the same as safe

Psilocybin is natural, but it still interacts with medications such as SSRIs and lithium, and potency varies between mushrooms — see the interactions and species entries.

The placebo question is real

Szigeti et al. 2021, a large self-blinded citizen-science study, found much of the reported benefit was matched by placebo. This is the strongest single challenge to microdosing claims.

But the question is not closed

Other observational and survey data shows directional effects, and the self-blinded design has its own limitations. The honest position is unsettled, not debunked.

The unifying lesson

Each myth resolves the same way: less intervention than people assume. A smaller dose, a scheduled break, a check before starting — restraint outperforms escalation.

What the data shows — and how strong it is

Strong Clinical + mechanisticModerate Survey + trackingEarly Promising, developingAnecdotal Widely reported only

Strong

Strong — dose definition“Microdose” is commonly used for an amount intended to remain below obvious psychedelic effects, but the term is informal and no universal threshold is standardized.

Moderate

Moderate — placebo contributionSzigeti et al. 2021 found that expectation accounted for much of the reported change within a self-blinded design. The method is informative but has important limitations.

Early

Early — microdose-specific signalWhether a real pharmacological microdose effect exists above placebo is not settled. Observational data is suggestive; controlled confirmation is limited.

Verdict

Common claims often overstate certainty. Controlled evidence supports caution, not a universal dose, schedule, or guaranteed benefit.

Common questions

Answered directly

Q · 01

Is microdosing just placebo?

It is unsettled, not settled. Szigeti et al. 2021, a large self-blinded study, found much of the reported benefit was matched by placebo, the strongest single challenge to microdosing claims. Other observational data shows directional effects, so the honest position is that expectation plays a real role and a microdose-specific signal above placebo is not established.

Q · 02

Is a bigger microdose more effective?

No. A microdose is sub-perceptual by definition. Increasing it does not scale the benefit — it produces a noticeable low dose that can impair function. If you feel a buzz or lift, the dose has crossed out of microdose range.

Q · 03

Is microdosing safe because psilocybin is natural?

Natural does not mean safe. Psilocybin interacts with medications such as SSRIs and lithium, and potency varies significantly between mushrooms. Natural origin says nothing about drug interactions or dose consistency — both still require care.

Product-format context

For product-format context, see the iMicrodosing.com products and client support.

View products & support →

← PreviousCritical period reopening Next →Set, setting, integration